The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - GATEKEEPER Pharmaceuticals; Loxo
Consulting or Advisory Role - Araxes Pharma; AstraZeneca; Biocartis; Boehringer Ingelheim; Chugai Pharma; Ignyta; Lilly; Loxo; Merrimack; Mirati Therapeutics; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Takeda; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI-owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention.
Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.
 
Pasi A. Janne
No Relationships to Disclose
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Lilly
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
 
Melissa Lynne Johnson
Consulting or Advisory Role - Araxes Pharma (Inst); Astellas Pharma (I); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Syndax (Inst); Syndax (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Merck; Pfizer; Sysmex; Vapotherm
 
Conor Ernst Steuer
Honoraria - Merck
Consulting or Advisory Role - Abbvie; ARMO BioSciences; BerGenBio
Research Funding - Vaccinex
 
Michele Vigliotti
Employment - Daiichi Sankyo
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Daiichi Sankyo
 
Corinne Iacobucci
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Celgene
Consulting or Advisory Role - Bayer; Daiichi Sankyo
 
Shuquan Chen
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Channing Yu
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Co-inventor on patent WO2013138585 A1 / US20150044676
 
Dalila B. Sellami
Employment - Daiichi Sankyo; Janssen Research & Development (I)
Stock and Other Ownership Interests - Daiichi Sankyo; Janssen-Ortho (I)
Other Relationship - Novartis